AGC Biologics Capacity Update October 2024: ADC

The Proveo™ alliance presents an innovative solution for antibody-drug conjugate (ADC) developers seeking comprehensive end-to-end support for their projects. By combining AGC Biologics’ expertise in monoclonal antibody production with Cerbios’ advanced bioconjugation and linker-payload technologies, alongside Oncotec’s capabilities in aseptic filling and lyophilization of ADC drug products, Proveo simplifies the development process into a single, streamlined contract.

This presentation will provide a global overview of the Proveo program, highlighting how it offers developers seamless, integrated support without the complications of managing multiple contracts, allowing for a more efficient path to bringing their ADC innovations to market.